{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T09:32:42Z","timestamp":1776504762033,"version":"3.51.2"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003125","name":"Finnish Cultural Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007083","name":"Orion Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007083","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ejmech.2018.07.040","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T19:07:07Z","timestamp":1532113627000},"page":"88-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Azulene-based compounds for targeting orexin receptors"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2582-7971","authenticated-orcid":false,"given":"Teppo O.","family":"Leino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainoleena","family":"Turku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jari","family":"Yli-Kauhaluoma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyrki P.","family":"Kukkonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"Xhaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik A.A.","family":"Wall\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.07.040_bib1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2018.07.040_bib2","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.ejmech.2018.07.040_bib3","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/acs.jmedchem.5b00832","article-title":"Orexin receptor antagonists: new therapeutic agents for the treatment of insomnia","volume":"59","author":"Roecker","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.040_bib4","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/med.21326","article-title":"The hypocretin\/orexin System: an increasingly important role in neuropsychiatry","volume":"35","author":"Chen","year":"2015","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2018.07.040_bib5","first-page":"1","article-title":"Orexin research: patent news from 2016","author":"Boss","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2018.07.040_bib6","series-title":"Small-molecule Agonist for Type-2 Orexin Receptor","author":"Yanagisawa","year":"2010"},{"key":"10.1016\/j.ejmech.2018.07.040_bib7","series-title":"2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione Compounds Having Orexin 2 Receptor Agonist Activity","author":"Cano","year":"2014"},{"key":"10.1016\/j.ejmech.2018.07.040_bib8","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1021\/acs.jmedchem.5b00988","article-title":"Design and synthesis of non-peptide, selective orexin receptor 2 agonists","volume":"58","author":"Nagahara","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.040_bib9","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.1021\/acs.jmedchem.6b00333","article-title":"Pharmacophore model to discover OX1 and OX2 orexin receptor ligands","volume":"59","author":"Turku","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.040_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178526","article-title":"Orexin receptor agonist Yan 7874 is a weak agonist of orexin\/hypocretin receptors and shows orexin receptor-independent cytotoxicity","volume":"12","author":"Turku","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.07.040_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/B978-0-444-59489-1.00010-0","article-title":"Orexin receptors as therapeutic drug targets","volume":"198","author":"Gotter","year":"2012","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.ejmech.2018.07.040_bib12","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/j.1476-5381.2011.01510.x","article-title":"The orexin receptor OX1R in colon cancer: a promising therapeutic target and a new paradigm in G protein-coupled receptor signalling through ITIMs","volume":"165","author":"Laburthe","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.07.040_bib13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1039\/c0sc00197j","article-title":"Discovery of an orexin receptor positive potentiator","volume":"1","author":"Lee","year":"2010","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2018.07.040_bib14","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1021\/ja01527a046","article-title":"Azulene. VIII. A study of the visible absorption spectra and dipole moments of some 1- and 1,3-substituted azulenes","volume":"81","author":"Anderson","year":"1959","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2018.07.040_bib15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1248\/cpb.36.641","article-title":"Synthesis and anti-ulcer activities of sodium alkylazulene sulfonates","volume":"36","author":"Yanagisawa","year":"1988","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2018.07.040_bib16","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1021\/jm00073a013","article-title":"Azulenic retinoids: novel nonbenzenoid aromatic retinoids with anticancer activity","volume":"36","author":"Asato","year":"1993","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.040_bib17","doi-asserted-by":"crossref","first-page":"6129","DOI":"10.1016\/j.bmcl.2010.08.025","article-title":"Novel azulene-based derivatives as potent multi-receptor tyrosine kinase inhibitors","volume":"20","author":"Chen","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.07.040_bib18","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0960-894X(01)00349-3","article-title":"Microwave-assisted [6+4]-Cycloaddition of fulvenes and alpha-pyrones to azulene \u2013 indoles\u202f: facile syntheses of novel antineoplastic agents","volume":"11","author":"Hong","year":"2001","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.07.040_bib19","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1016\/j.bmc.2013.03.067","article-title":"Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus\u202f: Discovery of YM543","volume":"21","author":"Ikegai","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.07.040_bib20","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1016\/j.bmcl.2012.09.064","article-title":"Novel azulene derivatives for the treatment of erectile dysfunction","volume":"22","author":"L\u00f6ber","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.07.040_bib21","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1021\/acs.joc.5b02271","article-title":"Synthesis of 1,3,6-trisubstituted azulenes","volume":"80","author":"Leino","year":"2015","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2018.07.040_bib22","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1002\/ejoc.201600962","article-title":"Synthesis of 1,3,6-trisubstituted azulenes based on the 1-acyloxyazulene scaffold","author":"Leino","year":"2016","journal-title":"Eur. J. Org Chem."},{"key":"10.1016\/j.ejmech.2018.07.040_bib23","series-title":"Small-Molecule Drug Discovery Suite 2015-3: Schr\u00f6dinger Suite 2015-3 Induced Fit Docking Protocol; Glide Version 6.8; Prime Version 4.1","author":"Schr\u00f6dinger","year":"2015"},{"key":"10.1016\/j.ejmech.2018.07.040_bib24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature14035","article-title":"Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant","volume":"519","author":"Yin","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.07.040_bib25","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1043-9471(05)80049-7","article-title":"Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors","volume":"25","author":"Ballesteros","year":"1995","journal-title":"Meth. Neurosci."},{"key":"10.1016\/j.ejmech.2018.07.040_bib26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jsb.2004.12.008","article-title":"Model structures of \u03b1-2 adrenoceptors in complex with automatically docked antagonist ligands raise the possibility of interactions dissimilar from agonist ligands","volume":"150","author":"Xhaard","year":"2005","journal-title":"J.\u00a0Struct. Biol."},{"key":"10.1016\/j.ejmech.2018.07.040_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12900-015-0036-2","article-title":"Modeling of the OX1R\u2013orexin-A complex suggests two alternative binding modes","volume":"15","author":"Karhu","year":"2015","journal-title":"BMC Struct. Biol."},{"key":"10.1016\/j.ejmech.2018.07.040_bib28","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1021\/ol0340078","article-title":"Facile oxidation of aldehydes to acids and esters with Oxone","volume":"5","author":"Travis","year":"2003","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2018.07.040_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cellsig.2015.11.009","article-title":"OX2 orexin\/hypocretin receptor signal transduction in recombinant Chinese hamster ovary cells","volume":"28","author":"Kukkonen","year":"2016","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2018.07.040_bib30","doi-asserted-by":"crossref","first-page":"5816","DOI":"10.1111\/bph.12883","article-title":"Calcium affects OX1 orexin (hypocretin) receptor responses by modifying both orexin binding and the signal transduction machinery","volume":"171","author":"Putula","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.07.040_bib31","doi-asserted-by":"crossref","first-page":"30806","DOI":"10.1074\/jbc.M002603200","article-title":"The orexin OX1 receptor activates a novel Ca2+ influx pathway necessary for coupling to phospholipase C","volume":"275","author":"Lund","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.07.040_bib32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/me.2004-0389","article-title":"OX1 orexin receptors activate extracellular signal- regulated kinase in Chinese hamster ovary cells via multiple mechanisms: the role of Ca2+ influx in OX1 receptor signaling","volume":"20","author":"Ammoun","year":"2006","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.ejmech.2018.07.040_bib33","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1476-5381.2011.01565.x","article-title":"OX1 orexin\/hypocretin receptor activation of phospholipase D","volume":"165","author":"J\u00e4ntti","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.07.040_bib34","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1124\/mol.112.078063","article-title":"OX1 orexin\/hypocretin receptor signaling through arachidonic acid and endocannabinoid release","volume":"82","author":"Turunen","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.07.040_bib36","series-title":"Small-Molecule Drug Discovery Suite 2015-1: Schr\u00f6dinger Suite 2015-1 Induced Fit Docking Protocol; Glide Version 6.6; Prime Version 3.9","author":"Schr\u00f6dinger","year":"2015"},{"key":"10.1016\/j.ejmech.2018.07.040_bib37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1124\/jpet.102.048025","article-title":"Distinct recognition of OX1 and OX2 receptors by orexin peptides","volume":"305","author":"Ammoun","year":"2003","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2018.07.040_bib38","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418305968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418305968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:46:05Z","timestamp":1759326365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418305968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":37,"alternative-id":["S0223523418305968"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.07.040","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Azulene-based compounds for targeting orexin receptors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.07.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}